Therapeutic drug monitoring of methotrexate in patients with Crohn's disease
Open Access
- 28 September 2023
- journal article
- research article
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 58 (11-12) , 1151-1162
Abstract
Summary: Background: Therapeutic drug monitoring (TDM) has the potential to improve efficacy and diminish side effects. Measuring methotrexate‐polyglutamate (MTX‐PG) in erythrocytes might enable TDM for methotrexate in patients with Crohn's disease (CD).Aim: To investigate the relationship between MTX‐PGs and methotrexate drug survival, efficacy and toxicityMethods: In a multicentre prospective cohort study, patients with CD starting subcutaneous methotrexate without biologics were included and followed for 12 months. Primary outcome was subcutaneous methotrexate discontinuation or requirement for step‐up therapy. Secondary outcomes included faecal calprotectin (FCP), Harvey Bradshaw Index (HBI), hepatotoxicity and gastrointestinal intolerance. Erythrocyte MTX‐PGs were analysed at weeks 8, 12, 24 and 52 or upon treatment discontinuation.Results: We included 80 patients with CD (mean age 55 ± 13y, 35% male) with a median FCP of 268 μg/g (IQR 73–480). After the 12‐month visit, 21 patients (26%) were still on subcutaneous methotrexate monotherapy. Twenty‐one patients stopped because of disease activity, 29 because of toxicity, and four for both reasons. Five patients ended study participation or stopped methotrexate for another reason. A higher MTX‐PG3 concentration was associated with a higher rate of methotrexate drug survival (HR 0.86, 95% CI 0.75–0.99), lower FCP (β −3.7, SE 1.3, p < 0.01) and with biochemical response (FCP ≤250 if baseline >250 μg/g; OR 1.1, 95% CI 1.0–1.3). Higher MTX‐PGs were associated with less gastrointestinal intolerance. There was no robust association between MTX‐PGs and HBI or hepatotoxicity.Conclusions: Higher MTX‐PG3 concentrations are related to better methotrexate drug survival and decreased FCP levels. Therefore, MTX‐PG3 could be used for TDM if a target concentration can be established.Keywords
Funding Information
- Maag Lever Darm Stichting
This publication has 33 references indexed in Scilit:
- Defining Disease Severity in Inflammatory Bowel Diseases: Current and Future DirectionsClinical Gastroenterology and Hepatology, 2016
- Association of Low Baseline Levels of Erythrocyte Folate With Treatment Nonresponse at Three Months in Rheumatoid Arthritis Patients Receiving MethotrexateArthritis & Rheumatism, 2013
- Sustained Clinical Benefit and Tolerability of Methotrexate Monotherapy After Thiopurine Therapy in Patients With Crohn's DiseaseClinical Gastroenterology and Hepatology, 2013
- Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritisCochrane Database of Systematic Reviews, 2013
- Patients Enrolled in Randomized Controlled Trials Do Not Represent the Inflammatory Bowel Disease Patient PopulationClinical Gastroenterology and Hepatology, 2012
- High prevalence of methotrexate intolerance in juvenile idiopathic arthritis: Development and validation of a methotrexate intolerance severity scoreArthritis & Rheumatism, 2011
- Red Blood Cell Methotrexate Polyglutamate Concentrations in Inflammatory Bowel DiseaseTherapeutic Drug Monitoring, 2007
- Evaluation of short-term responsiveness and cutoff values of inflammatory bowel disease questionnaire in Crohnʼs diseaseInflammatory Bowel Diseases, 2006
- A Comparison of Methotrexate with Placebo for the Maintenance of Remission in Crohn's DiseaseNew England Journal of Medicine, 2000
- A randomized dose–response and pharmacokinetic study of methotrexate for refractory inflammatory Crohn’s disease and ulcerative colitisAlimentary Pharmacology & Therapeutics, 1999